Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

A global phase 2 study, AKITA, was initiated in 2022. Learn more about the clinical development of RMC-035.

Read more

CLINICAL STUDIES

RMC-035, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

RMC-035

Acute kidney injury is a large market. 13 million people gloabally are affected every year.

Read more

INVESTOR RELATIONS

Press releases
  • 15 Apr 2024  ·  Regulatory information

    Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER

    Read more
  • 31 Jan 2024

    Guard Therapeutics presented development strategy and new preclinical results at R&D Update

    Read more
  • 18 Jan 2024

    Invitation to Guard Therapeutics’ R&D Update on January 30

    Read more
  • 15 Jan 2024  ·  Regulatory information

    FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035

    Read more
Show more
Calendar & reports
  • 22 Aug 2024

    Interim report April-June 2024

    Read more
  • 13 Nov 2024

    Interim report July-September 2024

    Read more
  • 20 Feb 2025

    Year-end report 2024

    Read more
Reports, presentations & in media
  • 30 Jan 2024 / Presentation

    Guard Therapeutics R&D update January 30, 2024

    Read more
  • 23 Nov 2023 / Presentation

    Tobias Agervald presents at ABGSC Investor Days

    Read more
  • 20 Sep 2023 / Analysis

    Erik Penser Bank - Guard Analysis 20 September 2023

    Read more
  • 19 Sep 2023 / Presentation

    Presentation from Investor Webcast - AKITA Top-line results

    Read more
Show more